PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsprecursor cell lymphoblastic leukemia-lymphoma
MeSH D054198 - precursor cell lymphoblastic leukemia-lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D007945:Lymphoid leukemia
45 Companies
14 Drugs
$
Success rate
D054198: 
Precursor cell lymphoblastic leukemia-lymphoma
48 Companies
20 Drugs
$
Success rate
D015452:Precursor b-cell lymphoblastic leukemia-lymphoma
1 Company
1 Drug
$
Success rate
D054218:Precursor t-cell lymphoblastic leukemia-lymphoma
1 Company
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDaunorubicin Daunorubicin  1998-06-23   
Doxorubicin Doxorubicin  1995-07-28   
Idarubicin Idarubicin  2002-05-01   
Ifosfamide, Mesna Ifosfamide/mesna  2002-02-26   
Imatinib Imatinib Teva  2013-01-07   
Doxorubicin Myocet (previously Myocet)  2000-07-13   
Cyclophosphamide Neosar  1993-04-29   
Dr Reddys LaboratoriesCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
Doxorubicin Doxorubicin  2017-05-15   
Mercaptopurine Mercaptopurine  2004-02-11   
MylanDoxorubicin Doxorubicin  2011-10-28   
Mercaptopurine Mercaptopurine  2005-07-01   
Rising PharmaceuticalsIdarubicin Idarubicin  2012-10-11   
Ifosfamide Ifosfamide  2012-11-26   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
SandozIdarubicin Idarubicin  2011-03-29   
Cyclophosphamide Cyclophosphamide  2023-09-12   
NovartisImatinib Glivec  2001-11-07   
SanofiDaunorubicin Cerubidine  1982-01-01   
Clofarabine Evoltra  2006-05-29   
WyethInotuzumab ozogamicin Besponsa  2017-08-17   
Daunorubicin Cerubidine  1982-01-01   
PfizerDoxorubicin Adriamycin  1991-01-30   
Inotuzumab ozogamicin Besponsa  2017-06-28 $236 M Y2023 
Doxorubicin Doxorubicin  1982-01-01   
Idarubicin Idamycin  1990-09-27   
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
65%
139/215
Phase 2
42%
83/199
Phase 3
59%
69/117
Approved: 21Overall Success rate: 16%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Cyclophosphamide,
Doxorubicin,
Doxorubicin hydrochloride,
Idarubicin,
Imatinib,
Imatinib mesylate
Dr Reddys Laboratories
Doxorubicin,
Doxorubicin hydrochloride
Mylan
Mercaptopurine
Novartis
Imatinib,
Imatinib mesylate,
Tbo-filgrastim,
Cilmostim,
Lenograstim,
Ademetionine,
Calcium dobesilate,
Doconexent,
Regramostim,
Sodium lactate,
Aspartame,
Bevifimod,
Microcrystalline cellulose,
Corticoids,
Caelyx,
Vsli,
Doxorubin,
Vp16,
Gcsf,
Solumedrol,
Triapine,
Articular,
Hsct,
Sti571,
Hydroxydaunomycin,
Itmha,
Evidence
Sanofi
Clofarabine,
Daunorubicin,
Daunorubicin hydrochloride,
Mycophenolate sodium,
Tbo-filgrastim,
Lenograstim,
Ademetionine,
Calcium dobesilate,
Terfenadine,
Aspartame,
COLTUXIMAB RAVTANSINE,
Caelyx,
Ratg,
Doxorubin,
SAR443579,
Allograft,
Vp16,
Gcsf,
Hsct,
Sti571,
Antacid,
Hydroxydaunomycin,
Evidence,
Sominex
Pfizer
Inotuzumab ozogamicin,
Doxorubicin,
Doxorubicin hydrochloride,
Idarubicin,
Salicylic acid,
Antithrombin iii,
Cilmostim,
Enoblituzumab,
Calcium dobesilate,
Terfenadine,
Pegargiminase,
Serine,
Sodium lactate,
Bevifimod,
Quilizumab,
Microcrystalline cellulose,
Allr3,
Caelyx,
Doxorubin,
Vp16,
Pd0332991,
Solumedrol,
Hsct,
Sti571,
Hydroxydaunomycin,
Itmha,
Sominex
Bristol Myers Squibb
Dasatinib,
Doxorubicin,
Doxorubicin hydrochloride,
Antithrombin iii,
Lampalizumab,
Calcium dobesilate,
Doconexent,
Serine,
Bevifimod,
OSUGACESTAT,
BMS-906024,
Caelyx,
Doxorubin,
Vp16,
Sti571,
Arm1,
Hydroxydaunomycin,
Cotrimoxazole,
Evidence
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use